BioSpace News Archive

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company’s lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022.

Paracrine, Inc., announced the online publication of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of the American College of Rheumatology.

Todos Medical, Ltd. (OTCQB: TOMDF), today announced that its majority-owned subsidiary 3CL Pharma, Ltd. announced that its mechanism-based 3CL protease inhibitors Tollovir® and Tollovid™ that target the active site of the 3CL protease showed robust inhibitory activity against the 3CL protease of the BA.1 and BA.2 strains of the Omicron SARS-CoV-2 variant of concern (VOC).

Bold Therapeutics, a Vancouver-based clinical-stage biopharmaceutical company, is excited to announce that they placed second in the Innovator’s Pitch Challenge at the 3-Day Digital Redefining Early-Stage Investments March Conference hosted by Life Science Nation.

Foresight Diagnostics today announced the hiring of Sandra Close, Ph.D., as Chief Operations Officer (COO).

MIM Software Inc. and Videra Surgical Inc. have announced a collaboration involving Videra Surgical’s VeraForm® tumor bed marker and MIM Software’s platform for Radiation Oncology.

Oxford Nanopore has announced the next steps in its collaboration with Genomics England, which is using nanopore technology in an ongoing proof-of-concept project to evaluate the clinical and research applications of comprehensive genomic analysis of cancer tumours.

Sirnaomics Ltd. (“Sirnaomics,” stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today dose administration for the first subject in a U.S. Phase I clinical trial of the Company’s systemic siRNA (small interfering RNA) therapeutic, STP707.

Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced the findings from its comprehensive study, Pseudo Contrastive Labeling for Predicting IVF Embryo Development Potential, published in Scientific Reports, a Nature Portfolio journal.

Reaction Biology announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer, Chief Business Officer and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company’s next stage of growth.